Document Detail

An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib.
MedLine Citation:
PMID:  16817333     Owner:  NLM     Status:  MEDLINE    
AIMS: Bortezomib (Velcade), a novel proteasome inhibitor, has shown promise in the treatment of malignancies, including multiple myeloma and non-Hodgkin's lymphoma. Several studies have identified neuropathy as a potentially dose-limiting side effect of treatment with bortezomib. We report the clinical and electrodiagnostic data from four patients who developed signs and symptoms of peripheral neuropathy from treatment with bortezomib. MATERIALS AND METHODS: Patients were included if they were enrolled in active phase 2 trials of bortezomib for non-Hodgkin's lymphoma or prostate cancer, developed signs and symptoms of peripheral neuropathy, and were referred for electrodiagnostic evaluation. RESULTS: Four patients, including two with non-Hodgkin's lymphoma and two with prostate cancer, underwent electrodiagnostic testing. Electrodiagnostic evaluation showed pre-existing peripheral nervous system disorders in three out of four patients. Multiple peripheral nervous system disorders were present in two out of four patients. CONCLUSIONS: Bortezomib can cause a predominately sensory axonal polyneuropathy. Pre-existing peripheral nervous system disorders, such as neuropathy and radiculopathy, are common in patients with cancer, and may pre-dispose to the development of symptomatic neuronal toxicity when treated with bortezomib. Baseline electrodiagnostic evaluation may identify patients with pre-existing peripheral nervous system disorders at risk for additive neuronal toxicity from neurotoxic chemotherapeutic agents.
M D Stubblefield; S Slovin; B MacGregor-Cortelli; J Muzzy; H Scher; J Wright; D Esseltine; D Schenkein; O A O'Connor
Related Documents :
6599223 - Bell's palsy and pupillary response.
1311373 - Autonomic dysfunction in diphtheritic neuropathy.
20697253 - Chronic gastritis in the setting of autoimmune pancreatitis.
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical oncology (Royal College of Radiologists (Great Britain))     Volume:  18     ISSN:  0936-6555     ISO Abbreviation:  Clin Oncol (R Coll Radiol)     Publication Date:  2006 Jun 
Date Detail:
Created Date:  2006-07-04     Completed Date:  2006-10-26     Revised Date:  2008-03-10    
Medline Journal Info:
Nlm Unique ID:  9002902     Medline TA:  Clin Oncol (R Coll Radiol)     Country:  England    
Other Details:
Languages:  eng     Pagination:  410-8     Citation Subset:  IM    
Memorial Sloan-Kettering Cancer Center, Department of Neurology, Rehabilitation Medicine Service, New York, NY 10021, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Boronic Acids / therapeutic use*
Lymphoma, Non-Hodgkin / complications,  drug therapy
Middle Aged
Peripheral Nervous System Diseases / diagnosis,  drug therapy*
Prostatic Neoplasms / complications,  drug therapy
Protease Inhibitors / therapeutic use*
Pyrazines / therapeutic use*
Grant Support
Reg. No./Substance:
0/Boronic Acids; 0/Protease Inhibitors; 0/Pyrazines; 0/bortezomib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Waiting times for cancer surgery in Ontario: 1984-2000.
Next Document:  Women's experience of termination of a pregnancy.